{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihzrldwwcow5j7c2i7ltmqqi42ylvuz7nakvhzp7m5conzodh7a2y",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mgnt6p75pxh2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreieqtzdf5vqgg6zqiul22gkprvapy2tw5rmxm54cvd2ns2hx2rmoda"
    },
    "mimeType": "image/jpeg",
    "size": 118056
  },
  "path": "/2026/03/09/vertex-iga-nephropathy-study-results/?utm_campaign=rss",
  "publishedAt": "2026-03-09T21:39:57.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "chronic diseases",
    "Pharmaceuticals",
    "STAT+",
    "Vertex"
  ],
  "textContent": "Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney disease known as IgA nephropathy.",
  "title": "STAT+: Vertex says its drug successfully reduced marker of kidney disease in late-stage trial",
  "updatedAt": "2026-03-09T21:40:01.000Z"
}